| Literature DB >> 30564374 |
Elton A M P Dudink1, Frederique E C M Peeters1, Sibel Altintas1, Luuk I B Heckman1, Rutger J Haest2, Hans Kragten3, Bas L J H Kietselaer1,4, Joachim Wildberger4, Justin G L M Luermans1, Bob Weijs1, Harry J G M Crijns1.
Abstract
Objectives: A standard coronary artery calcium scan includes part of the aorta. This additional information is often not included in routine analyses. We aimed to determine the feasibility of assessing the Agatston score of the descending aorta calcification (DAC) on standard coronary calcium scans and the association of this score with coronary events in a low-risk study population.Entities:
Keywords: X-ray computed; aorta; calcification; coronary artery disease; follow-up studies; physiologic; tomography
Year: 2018 PMID: 30564374 PMCID: PMC6269642 DOI: 10.1136/openhrt-2018-000893
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1There is a weak correlation between the Agatston score of the thoracic aorta and the Agatston score of the coronary arteries, as there are patients with coronary calcification but no aortic calcification and vice versa (top left; r=0.016, p=0.001). The Agatston score of the thoracic aorta is partly explained by the Agatston score of the ascending aorta (top right; r=0.499, p<0.001), but mainly by the Agatston score of the descending aorta (bottom left; r=0.997, p<0.001). In some patients, there is a correlation between the Agatston score of the ascending aorta and descending aorta, while others have no calcium in the ascending aorta but do have a high Agatston score of the descending aorta (bottom right; r=0.425, p<0.001).
Characteristics and events in patients with and without calcification in the ascending and descending aorta
| AsAC− (n=248) | AsAC+ (n=78) | P values | DAC− (n=244) | DAC+ (n=83) | P values | |
| Demographics | ||||||
| Age (years) | 53.8±10.4 | 60.1±6.9 |
| 53.4±10.0 | 61.1±7.2 |
|
| Sex (female) | 74 (29.8) | 36 (46.2) |
| 74 (30.3) | 37 (44.6) |
|
| Systolic blood pressure (mm Hg) | 126±11 | 126±11 | 0.22 | 126±11 | 126±10 | 0.59 |
| Diastolic blood pressure (mm Hg) | 80±10 | 79±10 | 0.53 | 80±10 | 79±12 | 0.31 |
| BMI (kg/m2) | 26 (3) | 26 (6) | 0.09 | 26 (5) | 27 (4) | 0.49 |
| BSA (m2) | 2.01 (0.28) | 1.93 (0.23) | 0.08 | 2.00 (0.31) | 1.95 (0.27) | 0.07 |
| Medical history | ||||||
| AF | 81 (32.7) | 21 (26.9) | 0.34 | 81 (33.2) | 21 (25.3) | 0.18 |
| AF duration (months) | 26 (68) | 30 (87) | 0.74 | 18 (68) | 43 (114) | 0.05 |
| Risk factors | ||||||
| Family history CAD | 78 (31.5) | 25 (32.1) | 0.92 | 77 (31.6) | 26 (31.3) | 0.97 |
| Smoking | 52 (21.0) | 16 (20.8) | 0.97 | 51 (21.0) | 17 (20.5) | 0.92 |
| Medication use | ||||||
| VKA | 24 (9.7) | 10 (12.8) | 0.43 | 22 (9.0) | 12 (14.5) | 0.16 |
| Aspirin | 65 (26.4) | 19 (24.0) | 0.68 | 63 (26.1) | 20 (24.7) | 0.80 |
| Beta blocker | 57 (23.3) | 16 (21.3) | 0.73 | 55 (22.9) | 19 (23.5) | 0.92 |
| Digoxin | 5 (2.0) | 6 (8.0) |
| 5 (2.1) | 6 (7.4) |
|
| Non-dihydropyridine CCB | 10 (4.1) | 2 (2.7) | 0.57 | 9 (3.8) | 3 (3.7) | 0.99 |
| ACE inhibitor | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| ARB | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| Diuretics | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| Dihydropyridine CCB | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| Statin | 17 (6.9) | 14 (17.9) |
| 19 (7.8) | 12 (14.5) | 0.07 |
| Echocardiography | ||||||
| Left atrial diameter (cm) | 3.8±0.5 | 3.9±0.4 | 0.09 | 3.8±0.5 | 3.8±0.5 | 0.93 |
| IVSd (mm) | 8.5±0.9 | 8.4±1.0 | 0.65 | 8.5±1.0 | 8.6±1.0 | 0.50 |
| LVPWd (mm) | 8.5±0.9 | 8.5±1.0 | 0.98 | 8.4±1.0 | 8.5±0.8 | 0.37 |
| EDV (ml) | 118±27 | 110±25 | 0.10 | 118±27 | 108±25 |
|
| ESV (ml) | 43±16 | 39±12 | 0.14 | 43±15 | 40±14 | 0.24 |
| LVEF (%) | 62 (9) | 63 (8) | 0.08 | 61 (8) | 62 (6) | 0.42 |
| CT diameters | ||||||
| Diameter AoV (mm) | 27±3 | 26±3 |
| 27±3 | 26±2 |
|
| Diameters sinus valsalva (mm) | 35±3 | 34±3 |
| 35±3 | 35±3 | 0.18 |
| Diameter STJ (mm) | 30±3 | 29±3 | 0.06 | 30±3 | 30±3 | 0.19 |
| Diameter ascending aorta (mm) | 32±4 | 32±3 | 0.94 | 32±4 | 32±3 | 0.13 |
| Diameter descending aorta (mm) | 27±2 | 27±2 | 0.26 | 26±2 | 27±2 | 0.05 |
| Agatston score coronary arteries | 0 (1.38) | 36 (296) |
| 0 (4.90) | 0 (198) |
|
| Agatston score ascending aorta | – | 23 (53) | – | 0 (0) | 1 (22) |
|
| Agatston score descending aorta | 0 [0] | 6 (87) |
| – | 10 (334) | – |
| Events | ||||||
| Stenosis >70% on CAG | 6 (2.4) | 4 (5.1) | 0.13 | 5 (2.8) | 5 (4.8) | 0.60 |
| uAP | 1 (0.4) | 0 (0.0) | 0.57 | 1 (0.4) | 0 (0.0) | 0.56 |
| NSTEMI | 3 (1.2) | 1 (1.3) | 0.96 | 3 (1.2) | 1 (1.2) | >0.99 |
| STEMI | 1 (0.4) | 0 (0.0) | 0.57 | 0 (0.0) | 1 (1.2) | 0.09 |
| Patients with coronary event | 11 (4.4) | 5 (6.4) | 0.49 | 9 (3.7) | 7 (8.4) | 0.08 |
| Medication only | 7 (2.8) | 3 (3.8) | 0.98 | 6 (2.5) | 4 (4.8) | 0.20 |
| PCI | 3 (1.2) | 2 (2.6) | 0.40 | 3 (1.2) | 2 (2.4) | 0.68 |
| CABG | 1 (0.4) | 0 (0.0) | 0.57 | 0 (0.0) | 1 (1.2) | 0.25 |
Shown is n (%), mean±SD or median (IQR).
ARB, angiotensin receptor blocker; AoV, aortic valve; AsAC, ascending aorta calcification; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CAG, coronary angiogram; CCB, calcium channel blocker; DAC, descending aorta calcification; EDV, end diastolic volume; ESV, end systolic volume; IVSd, interventricular septum diameter; LVEF, left ventricular ejection fraction; LVPWd, left ventricular posterior wall diameter; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; STJ, sinotubular junction; VKA, vitamin K antagonist; uAP, unstable angina pectoris.
AF, atrial fibrillation.
Figure 2The rate of coronary events per 1000 patient years in patients with and without coronary artery calcification and descending aorta calcification. CAC−, absence of coronary artery calcification; CAC+, presence of coronary artery calcification; DAC−, absence of descending aorta calcification; DAC+, presence of descending aorta calcification.
HRs from univariate and multivariate Cox regression with coronary event during follow-up as endpoint
| Univariate | Multivariate | |||
| HR (95% CI) | P values | HR (95% CI) | P values | |
| Age | 1.09 (1.02 to 1.16) | 0.01 | – | – |
| Agatston coronary arteries (per 100 units) | 1.32 (1.16 to 1.52) | <0.001 | 1.30 (1.13 to 1.51) | <0.001 |
| Agatston descending aorta (per 100 units) | 1.07 (1.03 to 1.10) | <0.001 | 1.06 (1.02 to 1.09) | 0.001 |
| Agatston combined ascending and descending aorta (per 100 units) | 1.07 (1.03 to 1.10) | <0.001 | – | – |
| Framingham Risk Score | 1.25 (1.07 to 1.46) | 0.005 | 1.24 (1.04 to 1.48) | 0.02 |
| Pooled Cohort Equations | 1.06 (0.98 to 1.14) | 0.14 | – | – |
Only significant predictors are shown.
Figure 3The receiver operating curve of three prediction models for the occurrence of coronary events during 5 years of follow-up: Framingham Risk Score (FRS) only, FRS+the Agatston score of the coronary arteries calcium (CAC) and FRS+CAC+the Agatston score of the descending aorta calcification (DAC). AUC, area under the curve.